Evgen Pharma PLC - Liverpool-based sulforaphane based medical drug developer - Says its "lead asset" SFX-01 is proven effective in glioblastoma cells and 3D spheroids following research from University of Auckland in New Zealand, which was investigating its use on tumours.
Earlier this month, US Food & Drug Administrator grants orphan drug designation for SFX-01 to treat blood cancer, malignant glioma. Orphan designation affords glioblastoma cells programme additional data protection and incentives.
"We noted the effects observed by the Auckland group in a previous communication and the data are now available for inspection via the journal," says Chief Executive Huw Jones. "They serve to confirm the potential efficacy of SFX-01 in cells that are arguably more disease relevant than those more commonly used.''
Current stock price: 6.10 pence
Year-to-date change: down 40%
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
